Folate-Binding Protein and Cisplatin Sensitivity in Ovarian Cancer
Author Information
Author(s): F Ottonel, S Miotti, C Bottini, M Bagnoli, P Perego, M Colnaghi, S Menard
Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Hypothesis
Is the overexpression of folate-binding protein associated with cisplatin sensitivity in ovarian carcinoma cell lines?
Conclusion
Higher levels of folate-binding protein expression are significantly associated with increased sensitivity to cisplatin in ovarian carcinoma cell lines.
Supporting Evidence
- FBP overexpression was observed in more sensitive ovarian carcinoma cell lines.
- Cisplatin-resistant cell lines showed decreased FBP expression.
- FBP expression correlated significantly with cisplatin sensitivity (r = 0.68; P = 0.027).
- Transfected cells did not show increased sensitivity to cisplatin despite higher FBP levels.
Takeaway
This study found that ovarian cancer cells with more folate-binding protein are better at responding to a cancer drug called cisplatin.
Methodology
The study used a colorimetric assay to measure cytotoxicity of cisplatin on various ovarian carcinoma cell lines and analyzed folate-binding protein expression through immunofluorescence.
Limitations
The study does not establish a direct causal relationship between folate-binding protein expression and cisplatin sensitivity.
Participant Demographics
Human ovarian carcinoma cell lines were used in the study.
Statistical Information
P-Value
p=0.027
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website